{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:49:16Z","timestamp":1771026556147,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.prp.2022.153834","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T19:55:43Z","timestamp":1646423743000},"page":"153834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review"],"prefix":"10.1016","volume":"232","author":[{"given":"Elena","family":"Calabria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Canfora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Varricchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Davide","family":"Mignogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.153834_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s40261-022-01127-9","article-title":"The impact of COVID-19 vaccination on the italian healthcare system: a scenario analysis","author":"Marcellusi","year":"2022","journal-title":"Clin. Drug Investig."},{"issue":"12","key":"10.1016\/j.prp.2022.153834_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"21","key":"10.1016\/j.prp.2022.153834_bib3","first-page":"02841","article-title":"Skin reactions to COVID-19 vaccines: an American Academy of Dermatology\/International League of Dermatological Societies registry update on reaction location and COVID vaccine type","author":"Freeman","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2022","key":"10.1016\/j.prp.2022.153834_bib4","article-title":"New-onset systemic lupus erythematosus after mRNA SARS-CoV-2 vaccination","volume":"11","author":"B\u00e1ez-Negr\u00f3n","year":"2022","journal-title":"Case Rep. Rheumatol."},{"issue":"Feb 5","key":"10.1016\/j.prp.2022.153834_bib5","first-page":"1","article-title":"ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review","author":"Prabhahar","year":"2022","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.prp.2022.153834_bib6","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","author":"Chen","year":"2021","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.prp.2022.153834_bib7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prp.2022.153834_bib8","article-title":"Oral pemphigus after COVID-19 vaccination","author":"Thongprasom","year":"2021","journal-title":"Oral. Dis."},{"issue":"4","key":"10.1016\/j.prp.2022.153834_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"47","key":"10.1016\/j.prp.2022.153834_bib10","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1016\/j.vaccine.2020.09.073","article-title":"Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: case report and literature review","volume":"38","author":"Bell","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.prp.2022.153834_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.prp.2022.153834_bib12","unstructured":"Food and Drug Administration Rituxan label . \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf\u3009. (Accessed 17 January 2022)."},{"issue":"10","key":"10.1016\/j.prp.2022.153834_bib13","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1111\/jdv.17480","article-title":"Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2","volume":"35","author":"Solimani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prp.2022.153834_bib14","article-title":"Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine","author":"Koutlas","year":"2021","journal-title":"Oral. Dis."},{"key":"10.1016\/j.prp.2022.153834_bib15","article-title":"Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient","author":"Knechtl","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prp.2022.153834_bib16","article-title":"An unusual presentation of pemphigus foliaceus following COVID-19 vaccination","author":"Lua","year":"2021","journal-title":"Austral J. Dermatol."},{"key":"10.1016\/j.prp.2022.153834_bib17","article-title":"Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review","author":"Pauluzzi","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"21","key":"10.1016\/j.prp.2022.153834_bib18","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"30","author":"Agharbi","year":"2021","journal-title":"Ann. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.prp.2022.153834_bib19","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/jdv.17676","article-title":"A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine","volume":"36","author":"Young","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prp.2022.153834_bib20","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies","author":"Gambichler","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2022.153834_bib21","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.medcli.2021.05.005","article-title":"Bullous pemphigoid and COVID-19 vaccine","volume":"157","author":"P\u00e9rez-L\u00f3pez","year":"2021","journal-title":"Med. Clin."},{"issue":"12","key":"10.1016\/j.prp.2022.153834_bib22","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1111\/1346-8138.16170","article-title":"Case of bullous pemphigoid following coronavirus disease 2019 vaccination","volume":"48","author":"Nakamura","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.prp.2022.153834_bib23","article-title":"New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin","author":"Bostan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.prp.2022.153834_bib24","article-title":"Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy","author":"Schmidt","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prp.2022.153834_bib25","article-title":"Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine","author":"Hali","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.prp.2022.153834_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ced.14835","article-title":"Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature","volume":"47","author":"Coto-Segura","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.prp.2022.153834_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cup.14104","article-title":"Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination","volume":"49","author":"Larson","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2022.153834_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.17955","article-title":"Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination","author":"Hung","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prp.2022.153834_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.16086","article-title":"Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center","author":"Afacan","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.prp.2022.153834_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15396","article-title":"Pemphigus vulgaris after SARS-CoV-2 vaccination: a case with new-onset and two cases with severe aggravation","author":"Akoglu","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.prp.2022.153834_bib31","unstructured":"WHO Coronavirus (COVID-19) Dashboard . \u3008https:\/\/covid19.who.int\u3009. (Accessed 17 January 2022)."},{"issue":"10","key":"10.1016\/j.prp.2022.153834_bib32","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"13","key":"10.1016\/j.prp.2022.153834_bib33","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2021004957","article-title":"Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination","volume":"5","author":"Portuguese","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.prp.2022.153834_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0b013e3282f0ad25","article-title":"Viral infection can induce the production of autoantibodies.","volume":"19","author":"Barzilai","year":"2007","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"10.1016\/j.prp.2022.153834_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcpa.2007.04.013","article-title":"From tolerance to autoimmunity: is there a risk in early life vaccination?","volume":"137","author":"Goriely","year":"2007","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.prp.2022.153834_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.prp.2022.153834_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:50:57Z","timestamp":1759733457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":37,"alternative-id":["S0344033822000772"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.153834","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.153834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153834"}}